Home/Filings/4/0001209191-19-028589
4//SEC Filing

Growth Equity Opportunities V, LLC 4

Accession 0001209191-19-028589

CIK 0001505512other

Filed

May 8, 8:00 PM ET

Accepted

May 9, 6:02 PM ET

Size

16.0 KB

Accession

0001209191-19-028589

Insider Transaction Report

Form 4
Period: 2019-05-07
Transactions
  • Purchase

    Common Stock Purchase Warrant (Right to Buy)

    2019-05-07$0.13/sh+3,703,704$462,9633,703,704 total
    Exercise: $1.08From: 2019-05-07Exp: 2024-05-07Common Stock (3,703,704 underlying)
  • Purchase

    Common Stock

    2019-05-07$1.08/sh+1,136,704$1,227,6402,052,454 total
  • Purchase

    Class A-1 Convertible Preferred Stock

    2019-05-07$10.80/sh+256,700$2,772,360256,700 total
    From: 2019-05-07Common Stock (2,567,000 underlying)
Transactions
  • Purchase

    Common Stock Purchase Warrant (Right to Buy)

    2019-05-07$0.13/sh+3,703,704$462,9633,703,704 total
    Exercise: $1.08From: 2019-05-07Exp: 2024-05-07Common Stock (3,703,704 underlying)
  • Purchase

    Common Stock

    2019-05-07$1.08/sh+1,136,704$1,227,6402,052,454 total
  • Purchase

    Class A-1 Convertible Preferred Stock

    2019-05-07$10.80/sh+256,700$2,772,360256,700 total
    From: 2019-05-07Common Stock (2,567,000 underlying)
Transactions
  • Purchase

    Common Stock Purchase Warrant (Right to Buy)

    2019-05-07$0.13/sh+3,703,704$462,9633,703,704 total
    Exercise: $1.08From: 2019-05-07Exp: 2024-05-07Common Stock (3,703,704 underlying)
  • Purchase

    Common Stock

    2019-05-07$1.08/sh+1,136,704$1,227,6402,052,454 total
  • Purchase

    Class A-1 Convertible Preferred Stock

    2019-05-07$10.80/sh+256,700$2,772,360256,700 total
    From: 2019-05-07Common Stock (2,567,000 underlying)
Transactions
  • Purchase

    Common Stock Purchase Warrant (Right to Buy)

    2019-05-07$0.13/sh+3,703,704$462,9633,703,704 total
    Exercise: $1.08From: 2019-05-07Exp: 2024-05-07Common Stock (3,703,704 underlying)
  • Purchase

    Common Stock

    2019-05-07$1.08/sh+1,136,704$1,227,6402,052,454 total
  • Purchase

    Class A-1 Convertible Preferred Stock

    2019-05-07$10.80/sh+256,700$2,772,360256,700 total
    From: 2019-05-07Common Stock (2,567,000 underlying)
Footnotes (4)
  • [F1]Acquired from the Issuer pursuant to a Securities Purchase Agreement dated May 3, 2019 with a closing date of May 7, 2019.
  • [F2]The securities are directly held by Growth Equity Opportunities Fund V, LLC ("GEO V") and indirectly held by New Enterprise Associates 16, L.P. ("NEA 16"), the sole member of GEO V, NEA Partners 16, L.P. ("NEA Partners"), the sole general partner of NEA 16, NEA 16 GP, LLC ("NEA 16 GP"), the sole general partner of NEA Partners 16, and the individual managers of NEA 16 GP (NEA 16, NEA Partners 16, NEA 16 GP and the individual managers of NEA 16 GP, together, the "Indirect Reporting Persons").
  • [F3]The individual managers of NEA 16 GP are Peter J. Barris, Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad Makhzoumi, Josh Makower, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Paul Walker. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities of the Issuer held by GEO V in which the Indirect Reporting Persons have no pecuniary interest.
  • [F4]Each share of Class A-1 Convertible Preferred Stock, par value $0.001 per share ("Class A-1 Preferred Stock"), of the Issuer is convertible at any time into a number of shares of common stock, par value $0.001 ("Common Stock"), of the Issuer at a rate of 10 shares of Common Stock for each share of Class A-1 Preferred Stock, for no additional consideration, in each case subject to customary adjustments under the certificate of designations for the Class A-1 Preferred Stock (the "Certificate of Designations"). Unless converted pursuant to its terms, the Class A-1 Preferred Stock does not expire. The Certificate of Designations prohibits conversion to the extent that the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the conversion.

Issuer

Regulus Therapeutics Inc.

CIK 0001505512

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001706444

Filing Metadata

Form type
4
Filed
May 8, 8:00 PM ET
Accepted
May 9, 6:02 PM ET
Size
16.0 KB